The Ligandable Human Proteome

Urokinase-type plasminogen activator

Index	Ligand Name	Structure	PDB code	ligand desolvation
1	qgg	UROKINASE-TYPE PLASMINOGEN ACTIVATOR INHIBITOR COMPLEX WITH A 1-(7- SULPHOAMIDOISOQUINOLINYL)GUANIDINE	2vnt	87.77
2	ui2	Substituted 2-Naphthamidine Inhibitors of Urokinase	1sqo	85.39
3	amr	UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-AMILORIDE COMPLEX	1f5l	84.2
4	9up	Crystal Structure of the Urokinase	4fug	83.06
5	4pg	Urokinase plasminogen activator B-chain-GPPE complex	2r2w	82.6
6	8up	Crystal Structure of the Urokinase	4fuf	79.94
7	1up	Crystal Structure of the Urokinase	4fu7	79.58
8	239	Crystal Structure of the Urokinase	4fuc	78.29
9	135	ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS	1gja	78.16
10	ui3	Substituted 2-Naphthamidine Inhibitors of Urokinase	1sqt	77.82
11	ui3	Crystal Structure of the Urokinase	4fui	76.89
12	134	ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS	1gj9	76.7
13	11e	Synthesis of a Weak Basic uPA Inhibitor and Crystal Structure of Complex with uPA	4h42	76.34
14	136	ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS	1gjd	76.14
15	hmx	uPA-HMA	5za7	75.89
16	que	Crystal structure of uPA in complex with quercetin	5xg4	75.15
17	239	Substituted 2-Naphthamidine Inhibitors of Urokinase	1owh	75.09
18	9x9	uPA-HMA	6ag2	74.71
19	9xf	Crystal structure of uPA in complex with 3,5-bis(azanyl)-6-(1-benzofuran-2-yl)-N-carbamimidoyl-pyrazine-2- carboxamide	6ag9	74.71
20	eau	uPA-6F-HMA	5zae	74.51
21	7up	Crystal Structure of the Urokinase	4fue	74.03
22	133	ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS	1gj8	72.52
23	l1r	Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator	2vip	72.23
24	cr9	Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA)	1o5c	72.21
25	09i	uPA-NU-09F	5zc5	71.8
26	655	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors	1o3p	71.62
27	d55	Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator	2viq	71.25
28	32i	uPA-31F	5zaj	71.21
29	ui1	Substituted 2-Naphthamidine Inhibitors of Urokinase	1sqa	70.92
30	h55	The crystal structure of uPA in complex with HMA-55F	6ag7	70.79
31	745	Substituted 2-Naphthamadine inhibitors of Urokinase	1u6q	70.13
32	94i	uPA-BB2-94F	5zag	69.17
33	426	Substituted 2-Naphthamidine Inhibitors of Urokinase	1owi	69.14
34	d56	Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator	2viw	68.78
35	1u9	Crystal Structure of the Urokinase	4fuj	68.44
36	50i	uPA-BB2-50F	5za9	68.34
37	28i	uPA-BB2-28F	5zaf	67.15
38	27i	uPA-BB2-27F	5za8	66.78
39	123	A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE	1gi9	66.08
40	30i	uPA-BB2-30F	5zah	65.61
41	497	Substituted 2-Naphthamidine inhibitors of urokinase	1owd	64.3
42	303	Substituted 2-Naphthamidine Inhibitors of Urokinase	1owk	64.19
43	vg2	Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator	2viv	63.21
44	9xc	Crystal structure of uPA in complex with 3,5-bis(azanyl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-carboxamide	6ag3	59.7